You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Ovarian cancer

Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer

  • Technology appraisal guidance
  • Reference number: TA389
  • Published:  27 April 2016
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Response to scrutiny letter

Response to scrutiny letter Response to scrutiny letter
25 March 2015
(180.36 Kb 52 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 25 March 2015

Back to top